Evidence map›Paper›PMID 40649239›Full record

ArticleMolecules (Basel, Switzerland)2025

Anti-Amyloid Aggregation Effects of Gobaishi (

Sharmin Akter, Takayuki Tohge, Sahithya Hulimane Ananda, Masahiro Kuragano, Kiyotaka Tokuraku, Koji Uwai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sharmin AkterLaboratory of Organic Chemistry in Life Science, Muroran Institute of Technology, Muroran 050-8585, Japan.
Takayuki TohgeLaboratory of Plant Secondary Metabolism, Nara Institute of Science and Technology, Nara 630-0192, Japan.ORCID 0000-0001-5555-5650
Sahithya Hulimane AnandaLaboratory of Protein Chemistry, Muroran Institute of Technology, Muroran 050-8585, Japan.
Masahiro KuraganoLaboratory of Protein Chemistry, Muroran Institute of Technology, Muroran 050-8585, Japan.ORCID 0000-0002-4958-1286
Kiyotaka TokurakuLaboratory of Protein Chemistry, Muroran Institute of Technology, Muroran 050-8585, Japan.ORCID 0000-0002-7747-4808
Koji UwaiLaboratory of Organic Chemistry in Life Science, Muroran Institute of Technology, Muroran 050-8585, Japan.ORCID 0000-0003-1385-9001

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a chronic neurodegenerative disorder that leads to memory loss and changes in mental and behavioral functions in elderly individuals. A major pathological feature of AD is the aggregation of amyloid-beta (Aβ) peptides, along with oxidative stress, inducing neurocellular apoptosis in the brain. Gobaishi (

Indexed as

Amyloid beta-PeptidesPlant ExtractsProtein AggregatesAlzheimer DiseaseBenzothiazolesCell Line, TumorDrugs, Chinese HerbalGallic AcidHumansHydrolyzable TanninsTanninsAmyloid beta-PeptidesBenzothiazolesDrugs, Chinese HerbalGalla chinensisGallic AcidHydrolyzable Tanninsmethyl gallatepentagalloylglucosePlant ExtractsProtein AggregatesTanninsamyloid-betaantioxidantGobaishimethyl gallatepentagalloyl glucose

Identifiers

PMID40649239
PMCPMC12250624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.